Published in Phys Rev Lett on September 25, 2003
Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ (1992) 26.37
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. J Gen Virol (1973) 6.60
Contribution of the private sector to elective surgery in England and Wales. Lancet (1984) 5.62
Analysis of the work of independent acute hospitals in England and Wales, 1981. Br Med J (Clin Res Ed) (1984) 4.29
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Isolation and identification of methanogen-specific DNA from blanket bog peat by PCR amplification and sequence analysis. Appl Environ Microbiol (1996) 3.47
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
Immune adherence by the fourth component of complement. Science (1969) 3.34
Terminal repetition in permuted T2 bacteriophage DNA molecules. J Mol Biol (1967) 2.99
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Amplification of DNA from native populations of soil bacteria by using the polymerase chain reaction. Appl Environ Microbiol (1992) 2.73
A semiconductor source of triggered entangled photon pairs. Nature (2006) 2.63
Terminal repetition in non-permuted T3 and T7 bacteriophage DNA molecules. J Mol Biol (1967) 2.61
Differences in durations of stay for surgery in the NHS and private sector in England and Wales. Br Med J (Clin Res Ed) (1985) 2.61
Genetic and biochemical studies with herpesvirus. Cold Spring Harb Symp Quant Biol (1975) 2.47
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract (2012) 2.40
Ohm's law survives to the atomic scale. Science (2012) 2.40
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Use of evidence based leaflets to promote informed choice in maternity care: randomised controlled trial in everyday practice. BMJ (2002) 2.35
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A (1993) 2.09
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Distribution, diversity and evolution of the bacterial mercury resistance (mer) operon. FEMS Microbiol Rev (1997) 2.00
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
Atomically precise placement of single dopants in si. Phys Rev Lett (2003) 1.88
What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open (2013) 1.87
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
On-demand single-electron transfer between distant quantum dots. Nature (2011) 1.75
Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol (1974) 1.74
Towards a quantum representation of the ampere using single electron pumps. Nat Commun (2012) 1.69
Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol (1968) 1.69
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol (1976) 1.67
An entangled-light-emitting diode. Nature (2010) 1.66
A randomised controlled trial of acupuncture care for persistent low back pain: cost effectiveness analysis. BMJ (2006) 1.65
The placebo-controlled trial as a test of complementary and alternative medicine: observations from research experience of individualised homeopathic treatment. Homeopathy (2004) 1.65
Patient reports of adverse events associated with acupuncture treatment: a prospective national survey. Qual Saf Health Care (2004) 1.63
Formation and function of a complex of the C3 proactivator with a protein from cobra venom. J Exp Med (1973) 1.63
Complement fixation by rheumatoid factor. J Clin Invest (1975) 1.60
Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry (1981) 1.58
Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol (1985) 1.58
Mechanism of injury of virus-infected cells by antiviral antibody and complement: participation of IgG, F(ab')2, and the alternative complement pathway. J Exp Med (1976) 1.57
Cell cycle-dependent immune lysis of Moloney virus-transformed lymphocytes: presence of viral antigen, accessibility to antibody, and complement activation. Proc Natl Acad Sci U S A (1971) 1.53
Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides. J Immunol (1978) 1.53
Serum and cerebral spinal fluid complement and serum autoantibodies in systemic lupus erythematosus. Medicine (Baltimore) (1971) 1.52
Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement. J Immunol (1981) 1.50
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Expression of a human cytomegalovirus receptor correlates with infectibility of cells. J Virol (1991) 1.48
Using Terahertz pulse spectroscopy to study the crystalline structure of a drug: a case study of the polymorphs of ranitidine hydrochloride. J Pharm Sci (2003) 1.47
Giant fluctuations of coulomb drag in a bilayer system. Science (2007) 1.45
Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol (1981) 1.44
Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol (1979) 1.44
Glomerular complement components in human glomerulonephritis. J Clin Invest (1974) 1.43
Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol (1980) 1.43
Tunable nonadiabatic excitation in a single-electron quantum dot. Phys Rev Lett (2011) 1.37
Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging (1997) 1.36
Electrically pumped photonic-crystal terahertz lasers controlled by boundary conditions. Nature (2009) 1.34
Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology (1998) 1.34
Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists. Proc Natl Acad Sci U S A (1984) 1.31
Atomic-scale, all epitaxial in-plane gated donor quantum dot in silicon. Nano Lett (2009) 1.30
Efficient single photon detection by quantum dot resonant tunneling diodes. Phys Rev Lett (2005) 1.29
The 'penumbra sign' on T1-weighted MR imaging in subacute osteomyelitis: frequency, cause and significance. Clin Radiol (1998) 1.29
Purification of the Epstein-Barr virus/C3d complement receptor of human B lymphocytes: antigenic and functional properties of the purified protein. J Virol (1986) 1.29
Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr (1995) 1.27
The subunit composition and sedimentation properties of human C1. J Immunol (1977) 1.27
The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein. J Virol (1990) 1.27
Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol (1991) 1.27
Polymerase chain reaction-restriction fragment length polymorphism analysis shows divergence among mer determinants from gram-negative soil bacteria indistinguishable by DNA-DNA hybridization. Appl Environ Microbiol (1993) 1.27
Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem (1989) 1.26
Inactivation of lysis of oncornaviruses by human serum. Virology (1976) 1.26
Identification of types of cells in human peripheral blood that bind C1q. J Immunol (1981) 1.25
Measuring the mental health status of a population: a comparison of the GHQ-12 and the SF-36 (MHI-5). Br J Psychiatry (1996) 1.24
Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-kappaB induction. J Exp Med (1997) 1.23
Activation of C1r by proteolytic cleavage. J Immunol (1976) 1.23
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis. J Immunol (1979) 1.20
Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest (1982) 1.20
Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett (2001) 1.20
CR2 ligands modulate human B cell activation. J Immunol (1988) 1.18
The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase. J Immunol (1980) 1.18
Accumulation and intracellular fate of tellurite in tellurite-resistant Escherichia coli: a model for the mechanism of resistance. FEMS Microbiol Lett (1994) 1.18
Terahertz pulsed imaging of skin cancer in the time and frequency domain. J Biol Phys (2003) 1.17
Stimulation of a human polymorphonuclear leukocyte oxidative response by the C1q subunit of the first complement component. J Immunol (1982) 1.17
Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol (2001) 1.17
Enzymatic activity of the second component of complement. Biochemistry (1975) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15